PetMedix logo
Startup

PetMedix

See PetMedix's full profile

BOOK A DEMO
Headquarters

United Kingdom

Founded Year

2017

Total Funding

$13.1M

Employees

11 - 50

Status

Active


About PetMedix

PetMedix is a development stage veterinary biopharmaceutical company based in Cambridge, UK. We are using the highest quality science to make the therapies our pets need and deserve, keeping them healthier, happier, and for longer.

Headquarters

United Kingdom


General Information on PetMedix

Brand name PetMedix
Company name PetMedix
Website https://www.petmedix.com/
Founded year 2017
Employees 11 - 50
Contact [email protected]
+4401223734140

Find startup solutions in your specific business context

The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.
BOOK A DEMO

Recent News and Activity about PetMedix

MRCVS.co.uk 10.01.2022
PetMedix and Zoetis to collaborate on antibody therapies

PetMedix has joined forces with Zoetis to develop new species-specific animal monoclonal antibody therapies (mAbs) using its proprietary transgenic platforms. Through the partnership, PetMedix will carry out discovery activities against a number of key targets, while Zoetis will have exclusive rights to develop and bring these therapies to market. Having already brought three novel mAbs to market, Zoetis is a leader in companion animal ...

PetMedix news
Vettimes 07.01.2022
PetMedix enters into antibody discovery collaboration with Zoetis

Vet Times Image © PetMedix. PetMedix has announced a collaboration with Zoetis to develop fully species-specific companion animal monoclonal antibody therapeutics (mAbs) using its proprietary transgenic platforms. As part of the collaboration, PetMedix will research key targets for therapies, and Zoetis will have an exclusive option to develop and bring these therapies to market. Zoetis is a market leader in companion animal antibody ...

PetMedix news
Angel News Newsletter 10.09.2021
Cambridge University biotech spinout PetMedix announces £27m Series B

PetMedix™ has announced the completion of an oversubscribed $37M (£27M) Series B financing round that will be used to advance its innovative pipeline through clinical development. The investment brings two new investors into PetMedix: global technology company Tencent and Japanese corporation Kyoritsu Holdings alongside strong continued support from U.S.-based investor Digitalis Ventures, and British funds Parkwalk Advisors and Cambridge ...

Business Leader 09.09.2021
PetMedix secures £27m in Series B funding round

The investment brings two new investors into PetMedix: global technology company Tencent and Japanese corporation Kyoritsu Holdings alongside strong continued support from U.S.-based investor Digitalis Ventures, and British funds Parkwalk Advisors and Cambridge Innovation Capital.“PetMedix has a global vision: elevating expectations in pet care the world over. This financing round not only provides the capital required to take us to the next ...

Global Corporate Venturing (Online) 08.09.2021
PetMedix gets $37m series B treat

UK-based pet-focused antibody treatment developer PetMedix closed a £27m ($37m) series B round today that included pharmaceutical and veterinary group Kyoritsu Holding and internet group Tencent. Cambridge Innovation Capital, a vehicle formed by University of Cambridge, also took part in the round, as did venture capital firm Digitalis Ventures and spinout-focused investment firm Parkwalk Advisors.…

VetReport.net 08.09.2021
PetMedix raises $37M Series B

“PetMedix has a global vision: elevating expectations in pet care the world over. This financing round not only provides the capital required to take us to the next level, but also the international perspective to help us meet our goals,” says Tom Weaver, PhD, PetMedix CEO and co-founder. This financing round will propel PetMedix from an R&D-stage, UK-focused biotech company, into a clinical-stage international organisation. PetMedix's internal ...

PetMedix news
UKTN 08.09.2021
Cambridge-based PetMedix bags £27M funding to revolutionise pet healthcare

Funding detailsThe latest funding round for PetMedix was led by Digitalis Ventures, and British funds Parkwalk Advisors. Additionally, Tencent and Japanese corporation Kyoritsu Holdings also participated, along with Cambridge Innovation Capital. The startup says this latest funding round will enable it to go from an R&D-stage to a clinical-stage international organisation.In a conversation with UKTN, PetMedix’s co-founder Jolyon Martin says, ” ...

PetMedix news
Veterinary Practice 28.07.2021
PetMedix monoclonal antibodies outperform benchmarks in canine study

PetMedix, a research and development stage biopharmaceutical company, announced on Wednesday 21 July 2021 that its first-ever fully canine monoclonal antibodies were used successfully in a canine trial, outperforming all relevant benchmarks. The PetMedix team discovered these antibodies using the unique proprietary Ky9 transgenic platform and conducted this first-of-its-kind study as part of an internal discovery campaign.This announcement ...

Business Weekly 23.07.2021
PetMedix transforming animal health with monoclonal antibodies

The PetMedix team discovered these antibodies using the unique proprietary Ky9™ transgenic platform and conducted this first-of-its-kind study as part of an internal discovery campaign.The advance positions PetMedix to lead the next generation of therapeutic antibody development in animal health, matching leading-edge human technology with unmet pet health needs.“This is a huge milestone for the company, one of which every single person working ...

PetMedix news